ZYME
Zymeworks Inc.
27.50$
-0.2%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +4.4% | -4.7% | -6.9% | -5.5% | -4.9% | -8.1% | -4.0% | -2.7% | -12.8% | +38.0% | -17.0% | |
| – | +10.2% | -4.6% | -2.6% | -10.4% | -12.6% | +2.0% | -3.4% | -1.5% | -20.0% | +65.2% | -22.6% | |
| – | +67.0% | -27.1% | -38.2% | +72.4% | -46.0% | +15.3% | +28.9% | -34.0% | -36.5% | +493.5% | -26.6% | |
| – | +26.7% | -7.8% | -4.3% | -10.0% | -24.0% | +17.5% | +6.1% | -10.5% | -9.2% | +59.4% | -25.8% | |
| – | -71.0% | +58.9% | +3.7% | -26.1% | +135.5% | -55.9% | -89.3% | +1,015.6% | -84.2% | +0.8% | +26.9% | |
| – | – | +0.0% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +99,900.0% | -99.9% | +0.0% | |
| – | -1.4% | -0.9% | -70.2% | -11.8% | -30.4% | -26.5% | -39.2% | -31.7% | +96,535.6% | -99.9% | -15.0% | |
| – | -12.1% | -0.3% | -5.4% | +9.8% | +3.5% | -19.1% | -26.5% | +4.5% | +1.1% | +303.2% | +0.6% | |
| – | -23.5% | +2.0% | -3.8% | +53.4% | +5.2% | -26.3% | -40.9% | +9.2% | +0.7% | -15.8% | +32.5% | |
| – | +10.9% | -2.5% | -31.7% | +3.7% | -6.9% | +18.9% | +10.1% | -5.2% | +2.1% | -5.5% | +0.8% | |
| – | -43.6% | -59.4% | -31.2% | +97.5% | +14.0% | +33.8% | -99.4% | +3,978.1% | +237.4% | +586.5% | -9.2% | |
| – | +9.5% | -5.8% | -7.3% | -9.6% | -7.7% | -4.1% | +2.9% | -4.3% | -16.1% | -39.1% | -50.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.4% | +7.6% | +0.2% | -0.3% | -0.4% | -0.9% | +2.9% | -2.1% | -0.6% | -0.9% | -2.3% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.